Prediction and verification of targets for α-hederin/oxaliplatin dual-loaded rHDL modified liposomes: Reversing effector T-cells dysfunction and improving anti-COAD efficiency in vitro and in vivo.

MLA

Wang, Gang, et al. “Prediction and Verification of Targets for α-Hederin/Oxaliplatin Dual-Loaded RHDL Modified Liposomes: Reversing Effector T-Cells Dysfunction and Improving Anti-COAD Efficiency in Vitro and in Vivo.” International Journal of Pharmaceutics, vol. 662, Sept. 2024, p. 124512. EBSCOhost, https://doi.org/10.1016/j.ijpharm.2024.124512.

APA

Wang, G., Xu, X.-N., Zhi-Min, Z., Wang, K., & Li, F. (2024). Prediction and verification of targets for α-hederin/oxaliplatin dual-loaded rHDL modified liposomes: Reversing effector T-cells dysfunction and improving anti-COAD efficiency in vitro and in vivo. International Journal of Pharmaceutics, 662, 124512. https://doi.org/10.1016/j.ijpharm.2024.124512

Chicago

Wang, Gang, Xiao-Na Xu, Zhu Zhi-Min, Kun Wang, and Fei Li. 2024. “Prediction and Verification of Targets for α-Hederin/Oxaliplatin Dual-Loaded RHDL Modified Liposomes: Reversing Effector T-Cells Dysfunction and Improving Anti-COAD Efficiency in Vitro and in Vivo.” International Journal of Pharmaceutics 662 (September): 124512. doi:10.1016/j.ijpharm.2024.124512.